“Will we ever be able to vaccinate against breast cancer? Asked a group of Mayo Clinic specialists after becoming aware of the importance of this figure. The idea is not left behind, since they have been trying to find a definitive answer to the problem.
After breast cancer, breast cancer is the most commonly diagnosed cancer in women in the United States – this can occur in men and women, but is much more common among women.
Statistics from the American Cancer Society reveal that approximately 268,000 new cases of invasive breast cancer will be diagnosed in American women each year.
Researchers at the Jacksonville, Florida, hospital and university federation have just stated that a vaccine they developed could be available within eight years and would not only be able to stop the recurrence of breast and ovarian cancers, it could also prevent them from developing.
“It is appropriate to say that we could have a vaccine within eight years, which patients could use through their pharmacy or their doctor,” said Dr. Keith L. Knutson, Mayo Clinic investigator, in an interview with Forbes, held three days ago
The research is only in its infancy. It would take at least three years before a phase 3 cancer vaccine trial is available for a large number of patients. He said.
They are also working on a third against in situ ductal carcinoma, or DCIS, a non-invasive breast cancer that alone brings in 300,000 new cases a year to oncologists in the United States.
Immunologists at the Mayo Clinic already had two cancer vaccines for triple negative breast cancer and HER2 positive breast cancer, respectively.
“We know they are safe. We know they stimulate the immune system [to fight cancer], “said Knutson.
“We know that they have had a positive impact on ovarian and breast cancer. We did not see any adverse events causing problems other than irritation in the area similar to influenza vaccination. We must now convince the FDA (Food and Drug Administration), through rigorous clinical trials, to see things as we see them
However, the process is not cheap; the costs of a typical phase 2 clinical trial can be as high as $ 12 or $ 20 million. And phase 3 trials can do double.
“What we are interested in is transferring vaccines from preclinical models to humans with cancer to prevent disease and, ultimately, to develop cancer vaccines,” says Knutson.
“We are also leading – my colleague and I – research on cancer vaccines focusing on immunity and T-cell therapy, as well as on tumors and the immune system. We are trying to learn how tumors escape the immune system. “
Researchers are also working on a cancer prevention project with the National Breast Cancer Coalition, a grassroots advocacy organization working to improve public policy on breast cancer research, diagnosis and treatment. Thus, they provide for the conduct of Phase 1 clinical trials for 2020.
Dr. Knutson’s and the clinic’s vaccines work by stimulating the body’s immune system – its natural defense mechanism – to attach to cancer cells and eliminate them.
“If you catch a cold or something similar, you develop an immune response, which does not necessarily prevent the disease, but it keeps it in check and helps to dispel it,” Knutson concludes.
Mayo Clinic specialists apply the same idea to cancer: a vaccine that drives an individual’s immune system to attack cancer cells.